Board of Directors

  • Jan H Egberts
    Jan H. Egberts Chairperson of the Board

    Dr. Egberts has over 25 years of experience in the pharmaceutical and medical devices sector. Currently, dr. Egberts serves as the Managing Partner of Veritas Investments, a private investment company focused on minority and controlling investments in healthcare companies.

    Dr. Egberts gained his medical degree from Erasmus University Medical School in the Netherlands and pursued the clinical part of his medical training at Harvard Medical School. Dr. Egberts also obtained an MBA from Stanford University.

    After Stanford, he joined McKinsey & Co. as a strategic consultant in New York. Dr. Egberts subsequently held various business development and general management positions of increasing responsibility in the USA at Merck & Co. and Johnson & Johnson. Thereafter, he served as Senior Advisor, Healthcare Investments for 3i, the private equity firm. Dr. Egberts then became CEO of OctoPlus, a publicly traded specialty pharmaceutical company in the Netherlands. OctoPlus was subsequently acquired by dr. Reddy Laboratories. After this, dr Egberts joined Agendia, a molecular diagnostics company, initially as board member and subsequently full time as interim CEO. Dr Egberts also has held over 15 executive and non-executive supervisory board positions in the U.S.A. and various European countries.

    Jan Egberts holds 14 500 shares in Photocure.

    Read more Read less
  • Dr Johanna Holldack
    Johanna Holldack Director

    Dr. Holldack has international operational experience from pharma companies, including clinical trials, drug approvals, IPOs and licensing. She has also managed several mergers and acquisitions. In addition, Dr. Holldack has venture capital experience from Swiss-based Aravis Venture where she was a partner for 5 years. Her industry career spans over 20 years, during which she held key positions in both start-up and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene, Borean Pharma, Telormedix and Trethera Corporation. She is chairman of Amal Therapeutics.

    Dr. Holldack has a medical degree from Georg-August-University in Gottingen, Germany and is a Board Certified pediatrician. In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School.

    Johanna Holldack holds 0 shares in Photocure.

    Read more Read less
  • Gwen Melincoff
    Gwen Melincoff Director

    Ms. Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, product management and project management.

    From 2014 to 2016, she served as Vice President of Business Development at BTG International Inc. From 2004 to the 2013, Ms. Melincoff was Senior Vice President of Business Development at Shire Pharmaceuticals. Additionally, she led the Strategic Investment Group (SIG), Shire's $50MM corporate venture fund which was started in 2010.
    Ms. Melincoff has a B.S in Biology, a Master's of Science in Management, and has attained the designation of the Certified Licensing Professional (CLP™).

    Gwen Melincoff holds 1,000 shares in Photocure.

    Read more Read less
  • Tom Pike
    Tom Pike Director

    Tom Pike serves as Chairperson of Vaccibody, and has been associated with the pharmaceutical industry in Norway for many years. Previous positions includes Partner in the venture capital fund NeoMed, Chairperson & CEO of Clavis Pharma ASA as well as Chairperson of the Association of the Pharmaceutical Industry in Norway. He has worked at Hoffman-La Roche in Norway and Switzerland for 18 years, including 8 years as general manager in Norway. Mr. Pike holds a B.Sc. Honors in Pharmacology.

    Tom Pike holds 3 400 shares in Photocure. He holds no share options in the company.

    Read more Read less
  • Grannum Sant
    Grannum R. Sant Director

    Grannum R. Sant is currently an independent consultant for medical organizations and biopharmaceutical industry, and Professor of Urology at Tufts University School of Medicine in Boston, USA. Dr. Sant has a broad and deep international experience in pharma and academia. From 2003 to 2013 he held senior leadership roles including Vice President and Head of Medical Affairs for urology and oncology at Sanofi US. His last pharma position (2010-2013) was as Vice President, Head of Global Medical Affairs Rare Genetic Diseases at Genzyme. Dr. Sant is a board certified urologist in the US and prior to 2003 was Professor and Chair of the Urology at Tufts University School of Medicine.

    Grannum Sant holds no shares or share options in Photocure.

    Read more Read less